PaTHway Phase 3 Trial Analysis

Bone Turnover Markers: P1NP and CTx (Mean +/- SE) by Visit Pathway Mean P1NP TransCon PTH Placebo 150 130 110 Mean CTx TransCon PTH Placebo 1500 Procollagen 1N-Terminal 90 90 Propeptide 70 ng/mL Mean (± SE) 1000 Type I Collagen C- Telopeptides ng/L Mean (± SE) 500 50 30 10 0 4 8 12 16 20 24 28 0 8 12 16 Weeks Weeks Similar pattern exhibited at Week 26 in Phase 2 PaTH Forward Trial P1NP, procollagen type 1 N-terminal propeptide CTX, C-terminal telopeptides of type I collagen 21 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. 20 20 24 24 ascendis pharma TRIAL 28

View entire presentation